#USA #Miami #Board of Directors #Pacira BioSciences #DOMA Capital

DOMA Perpetual Capital Management Sets to Nominate New Directors

On December 30, 2025, DOMA Perpetual Capital Management LLC, which holds around 6.83% of the outstanding shares of Pacira BioSciences, Inc. (NASDAQ: PCRX), announced its plan to nominate three independent candidates for the board of directors during the upcoming annual meeting scheduled for 2026. This initiative underscores DOMA's commitment to enhancing governance standards and ensuring shareholder interests are adequately represented.

Calls for a Sale of the Company

In addition to the nominations, DOMA expressed the need for Pacira's board to undertake a comprehensive review of the company's operations with the aim of pursuing a potential sale. The firm believes that this step is essential for maximizing value for shareholders, given that the current executive compensation and general expenditures are viewed as excessive and unwarranted. DOMA's position highlights concerns about whether the board has maintained adequate fiduciary responsibility in overseeing Pacira's performance and decision-making.

Background on DOMA Perpetual Capital Management

Based in Miami, Florida, DOMA Perpetual Capital Management specializes in asset management with a focus on identifying companies that possess sustainable competitive advantages. Its strategy aims to limit exposure to downside risks while pursuing investment opportunities across various market sectors worldwide. The firm utilizes a robust analytical approach to determine investment potentials, blending a fundamentals-based strategy with tactical positioning in the financial markets.

In light of the recent announcement, DOMA remains committed to advocating for stronger governance structures within Pacira, showcasing its ongoing efforts to engage proactively with the company's management and board. This commitment not only seeks to protect its financial interests but also aims to align the company's strategic direction with the evolving market landscape.

As part of their proxy solicitation process, DOMA will be preparing a preliminary proxy statement to present to other shareholders, stressing the importance of transparency and communication regarding their intended actions at the upcoming meeting. Shareholders are encouraged to stay informed and provide their insights that will guide the future direction of Pacira BioSciences.

Conclusion

With growing pressure for change in corporate governance, DOMA Perpetual Capital Management's actions reflect a broader trend of shareholder activism in today's business environment. Investors are increasingly seeking boards that prioritize accountability and strategic oversight to bolster company performance and safeguard shareholder value. As the 2026 annual meeting approaches, all eyes will be on how this situation unfolds and what it potentially means for Pacira's future operations and market position.